CONTENTSService Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
LEASE of Unit B1 Melbourn Science and Business Park, Melbourn, South CambridgeshireLease • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLCDeposit Agreement • February 27th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
DEPOSIT AGREEMENT dated as of December 14, 2000 among OXFORD GLYCOSCIENCES PLC, a public limited companyJune 7, 2001, among CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC, incorporated under the laws of England and Wales (herein called the Issuer), THE BANK OF NEW YORK, a New York banking corporation (herein called the Depositary), and all Owners and Beneficial Ownersholders from time to time of American Depositary Receipts issued hereunder.
EXHIBIT 4.8 Collaboration Agreement Dated August 9, 1999 Between Human Genome Sciences Inc.Collaboration Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • England
Dated February 28, 1999 Between Knoll AG AndDevelopment and License Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • England
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT/1/Research and Development • February 21st, 2002 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
WITNESSETH:Research and License Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • Illinois
ANDDeposit Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
Counterpart AGREEMENT FOR LEASEAgreement for Lease • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT/1/Research, Development and Commercialization Agreement • October 14th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT1License and Collaboration Agreement • December 4th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
THIS AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (the “Agreement”), dated as of September 19, 2003, is made between Genzyme Corporation, a Massachusetts corporation having its principal place of business at One Kendall Square, Cambridge, Massachusetts 02139, U.S.A. (“Genzyme”) and Optein Inc., d/b/a Aptein Inc. (“Aptein”), a Delaware corporation and an Affiliate (as defined herein) of Cambridge Antibody Technology Limited (“CAT”), a company organized under the laws of England and Wales having its principal place of business at The Milstein Building, Granta Park, Cambridge CB1 6GH, England. Genzyme and Aptein are sometimes referred to herein individually as a “Party” and together as the “Parties.”
EXHIBIT 4.7 LICENSE AND COLLABORATION AGREEMENT /1//License and Collaboration Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
DATED: October 25, 2005 Cambridge Antibody Technology Limited - and - Cambridge Antibody Technology Group plc - and - Abbott Biotechnology Ltd. - and - Abbott GmbH & Co. KG - and - Abbott Laboratories Settlement and Amendment AgreementSettlement and Amendment Agreement • March 3rd, 2006 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • England
This Settlement Agreement to the Original Agreement, as both hereinafter later defined, is made this 25th day of October 2005 (the “Commencement Date”) by and between:
EXHIBIT 4.10 RESEARCH COLLABORATION AND SERVICE AGREEMENT/1/ (EXECUTION COPY) THIS COLLABORATION AGREEMENT (together with the attached Exhibits, the "Agreement") is made as of March 29, 1999 (the "Effective Date") by and among Genetics Institute,...Research Collaboration and Service Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
SERVICE AGREEMENTService Agreement • December 4th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
BETWEENAntibody License Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
Exhibit 4.15 COMMERCIAL MANUFACTURING SERVICES AGREEMENTCommercial Manufacturing Services Agreement • December 19th, 2002 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • England
COLLABORATION AND LICENCE AGREEMENT1 by and between ASTRAZENECA UK LIMITED and CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED and CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC DATE: 21 NOVEMBER 2004Collaboration and License Agreement • December 16th, 2004 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • England and Wales
NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:
ANTIBODY LIBRARY LICENCE AGREEMENT1Antibody Library Licence Agreement • December 4th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • England and Wales
Subscription Agreement Cambridge Antibody Technology Group plc and AstraZeneca UK LimitedSubscription Agreement • December 27th, 2004 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • England
DATED 2005 (1) Cambridge Antibody Technology Group plc and (2) GENENCOR INTERNATIONAL, INC. SUBSCRIPTION AGREEMENT MORRISON | FOERSTER Multinational Partnership CityPoint, One Ropemaker Street | London EC2Y 9AW Tel: +44 20 7920 4000 | Fax: +44 20 7496...Subscription Agreement • May 23rd, 2006 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC and OXFORD GLYCOSCIENCES PLC and THE BANK OF NEW YORK As Depositary and OWNERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY RECEIPTS Amendment No. 1 dated as of______________, 2003 (to OGS Deposit Agreement...Deposit Agreement • February 27th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
This AMENDMENT NO. 1, dated as of __________, 2003 to the OGS Deposit Agreement (as hereinafter defined), among CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC, incorporated under the laws of England and Wales (herein called the “Company”), OXFORD GLYCOSCIENCES PLC, incorporated under the laws of England and Wales (herein called “OGS”), THE BANK OF NEW YORK, a New York banking corporation (herein called the “Depositary”), and all Owners and holders from time to time of American Depositary Receipts issued hereunder.
Cambridge Antibody Technology Group plc Milstein Building Granta Park Cambridge CB1 6GHDeposit Agreement • February 27th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
Re: Deposit Agreement (the "Deposit Agreement") substantially in the form of that filed as an exhibit to the Form F-6 Registration Statement filed with the Securities and Exchange Commission on April 9, 2001, by and among Cambridge Antibody Technology Group plc, The Bank of New York, as Depositary, and al Owners and holders from time to time of American Depositary Receipts issued thereunder
EXHIBIT 2.3 Exhibit A to Deposit AgreementDeposit Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
